Meihua International Medical Technologies Facilitates World's Second* 5G Remote Robot-Assisted Lobectomy

Rhea-AI Summary

Meihua International Medical Technologies (NASDAQ: MHUA) announced its NT-2000 surgical path analysis system supported the world's second 5G remote robot-assisted lobectomy, believed to be the first in China's Yangzi Delta area. The procedure was performed on July 15, 2024, at Yangzhou University Affiliated Hospital by a team from Shanghai Chest Hospital, over 200 kilometers away. MHUA's Chairman, Yongjun Liu, highlighted the operation's success, completed in just one hour using 5G technology and robotic precision.

The company is developing robotic surgical systems as part of its strategy to increase high-end product sales and expand its customer base. MHUA has introduced overseas technologies and established an R&D team focused on robotic-assisted surgery (RAS) systems. The RAS project, in collaboration with Hope City Medical Park in Hainan province, is expected to be completed in fall 2025.

Positive

• Successfully supported world's second 5G remote robot-assisted lobectomy
• NT-2000 system's real-time monitoring and guidance capabilities improve surgical accuracy
• Strategic initiative to increase sales of high-end products and broaden customer base
• Established dedicated R&D team for robotic-assisted surgery (RAS) systems
• RAS project in collaboration with Hope City Medical Park, expected completion in fall 2025

Negative

• None.

Medical Technology Analyst

Meihua International Medical Technologies' involvement in the world's second 5G remote robot-assisted lobectomy marks a significant milestone in telemedicine and robotic surgery. The NT-2000 surgical path analysis system's role in this procedure underscores MHUA's growing presence in the high-end medical device market.

Key points to consider:

• The successful operation demonstrates the viability of remote robotic surgery, potentially revolutionizing access to specialized surgical care in underserved areas.
• MHUA's strategic focus on robotic-assisted surgery (RAS) systems aligns with the growing trend towards minimally invasive procedures, which offer benefits such as reduced risk and faster recovery times.
• The company's collaboration with Hope City Medical Park for RAS development suggests a commitment to long-term innovation in this space.

However, investors should note that while this achievement is impressive, it's still early days for remote robotic surgery. The technology's widespread adoption will depend on factors such as regulatory approvals, cost-effectiveness and healthcare infrastructure development. MHUA's ability to capitalize on this emerging market will be important for its future growth prospects.

Healthcare Market Strategist

MHUA's participation in this groundbreaking procedure signals its strategic positioning in China's evolving healthcare landscape. The company is smartly leveraging two key trends:

• The push for healthcare equality across regions, addressing the urban-rural divide in medical resources.
• The growing demand for advanced medical technologies in China's rapidly aging population.

By focusing on high-end products like the NT-2000 system, MHUA is targeting a lucrative segment of the medical device market. This move could potentially lead to higher profit margins and a more diversified revenue stream.

However, the success of this strategy hinges on several factors:

• The pace of 5G infrastructure development across China, especially in less developed areas.
• The willingness of hospitals and healthcare systems to invest in robotic surgery platforms.
• Competition from both domestic and international medical device manufacturers in the RAS space.

Investors should monitor MHUA's progress in commercializing its RAS technology and its ability to secure partnerships with major hospitals. The projected completion of the RAS project in fall 2025 provides a concrete timeline for assessing the company's execution of this strategic initiative.

YANGZHOU, China, July 31, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, today announced that its NT-2000 surgical path analysis system successfully supported the world's second* 5G remote robot-assisted lobectomy. This procedure, we believe the first of its kind in China's Yangzi Delta area, was performed on July 15, 2024, at Yangzhou University Affiliated Hospital by a team from Shanghai Chest Hospital.

"We are honored that our cutting-edge technology could assist the advanced 3D imaging for surgical mapping in this sophisticated procedure," said Mr. Yongjun Liu, Chairman of Meihua, "Despite a physical distance of over 200 kilometers between the surgical team and the patient, the operation was executed seamlessly in just one hour, thanks to 5G technology and the precision of the robotic surgical system. We believe that robot-assisted surgery has made significant strides due to its clinical effectiveness, low risk, and quick recovery times. We also believe that successful implementations improve the quality of medical services, allowing patients to access diverse, personalized, and high-quality healthcare locally. We anticipate that this innovation will not only ease the workload on medical staff but also address disparities in medical resource distribution across China. Moving forward, Meihua will continue in its efforts to innovate and enhance healthcare outcomes for patients."

The development of Meihua's robotic surgical systems is part of the Company's strategic initiatives to increase sales of high-end products and broaden its customer base. The Company has introduced new overseas technologies, including minimally invasive surgical robot systems, and established a dedicated research and development team focused on robotic-assisted surgery (RAS) systems. The Company believes its NT-2000 system's real-time monitoring and guidance capabilities enable precise targeting of surgical sites, improving the accuracy and success rates of operations. The RAS project is being developed in conjunction with the Hope City Medical Park in Hainan province, China. The project is expected to be completed in the fall of 2025.

* We believe this is the World's second 5G remote robot-assisted lobectomy, as reported by Yangzhou University Affiliated Hospital:  https://mp.weixin.qq.com/s/HuApwLs3V8rRib1nSpUMXQ and Yangzhou Daily: http://news.yznews.com.cn/2024-07/27/content_7674119.htm.

About Meihua International Medical Technologies Co., Ltd.

Meihua International Medical Technologies is a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China. The Company manufactures and sells Class I disposable medical devices, such as HDPE bottles for tablets and LDPE bottles for eye drops, throat strips and anal bags, as well as Class II and III disposable medical devices, such as disposable identification bracelets, gynecological examination kits, inspection kits, surgical kits, medical brushes, medical dressing, medical catheters, uterine tissue suction tables, virus sampling tubes, disposable infusion pumps, electronic pumps and anesthesia puncture kits, among other products which are sold under Meihua's own brands and are also sourced and distributed from other manufacturers. The Company has received an international "CE" certification and ISO 13485 system certification and has also registered with the FDA (registration number: 3006554788) for more than 20 Class I products. The Company has served hospitals, pharmacies, medical institutions and medical equipment companies for more than 30 years, providing over 1,000 types of products for domestic sales, as well as more than120 products which are exported to more than 30 countries internationally across Europe, North America, South America, Asia, Africa and Oceania.

For more information, please visit www.meihuamed.com.
Follow us on Webull: https://www.webull.com/quote/nasdaq-mhua.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's ability to achieve its goals and strategies, the Company's future business development and plans of future business development, including its ability to successfully develop robotic assisted surgery systems and obtain licensure and certification for such systems, financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, fluctuations in general economic and business conditions in China, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission ("SEC"). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, including under the section entitled "Risk Factors" in its annual report on Form 20-F, as well as on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For investor and media inquiries, please contact:

IR Department 
Email: secretary@meihuamed.com
Tel: +86-0514-89800199

Christensen 
Yang Song
Email: yang.song@christensencomms.com
Tel: +86-010-59001548

View original content:https://www.prnewswire.com/news-releases/meihua-international-medical-technologies-facilitates-worlds-second-5g-remote-robot-assisted-lobectomy-302210979.html

SOURCE Meihua International Medical Technologies Co., Ltd.

FAQ

When did Meihua International Medical Technologies (MHUA) support the 5G remote robot-assisted lobectomy?

Meihua International Medical Technologies (MHUA) supported the 5G remote robot-assisted lobectomy on July 15, 2024.

What is the significance of MHUA's NT-2000 surgical path analysis system?

MHUA's NT-2000 surgical path analysis system provides real-time monitoring and guidance capabilities, enabling precise targeting of surgical sites and improving the accuracy and success rates of operations.

When is MHUA's robotic-assisted surgery (RAS) project expected to be completed?

MHUA's robotic-assisted surgery (RAS) project, being developed in conjunction with Hope City Medical Park in Hainan province, China, is expected to be completed in the fall of 2025.

What are the strategic initiatives of Meihua International Medical Technologies (MHUA)?

MHUA's strategic initiatives include increasing sales of high-end products, broadening its customer base, introducing new overseas technologies, and developing robotic surgical systems.